InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-17.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Klein Lawrence Otto, Chief Operating Officer. Director active across 2 companies, notably CRISPR Therapeutics AG. Aggregated, 6 filings have been recorded. Activity tracked since 12 October 2022. The latest transaction was filed on 12 October 2022 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations6 total
24,500 shares0Voting Common StockSEC:0001213900-22-063947:0
4,584 sharesCommon SharesSEC:0001209191-22-018611:0
26,667 sharesCommon SharesSEC:0001209191-21-068455
26,667 sharesCommon SharesSEC:0001209191-21-068455:0
10,000 sharesCommon SharesSEC:0001209191-21-056092:0
10,000 sharesCommon SharesSEC:0001209191-21-056092
6 of 6 declarations
About Klein Lawrence Otto
Lawrence Otto Klein is the Chief Business Officer and Chief Operating Officer at CRISPR Therapeutics AG. He oversees the company's commercial and strategic operations, playing a crucial role in implementing growth strategy. With a strong background in the biopharmaceutical sector, Lawrence Otto Klein is committed to advancing the company's objectives and maximizing its market impact.
